GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market.
Shingrix is viewed by analysts as among the British company’s most promising experimental products, since it has shown greater protection among older recipients than Merck’s rival shot Zostavax.
{iframe}http://www.cnbc.com/2016/10/24/gsk-files-potential-1-billion-shingles-vaccine-for-us-approval.html{/iframe}